MA27592A1 - Agonistes du recepteur du facteur de liberation 2 de la corticotropine. - Google Patents

Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Info

Publication number
MA27592A1
MA27592A1 MA27780A MA27780A MA27592A1 MA 27592 A1 MA27592 A1 MA 27592A1 MA 27780 A MA27780 A MA 27780A MA 27780 A MA27780 A MA 27780A MA 27592 A1 MA27592 A1 MA 27592A1
Authority
MA
Morocco
Prior art keywords
receptor agonists
release factor
corticotropin release
derivatives
corticotropin
Prior art date
Application number
MA27780A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27592A1 publication Critical patent/MA27592A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des dérivés isolés du facteur de libération de la corticotropine et des acides nucléiques codant lesdits dérivés. Ces dérivés sont efficaces dans le traitement de troubles modulés par le récepteur 2 du facteur de libération de la corticotropine, tels qu'une dystrophie musculaire.
MA27780A 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine. MA27592A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
MA27592A1 true MA27592A1 (fr) 2005-11-01

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Country Status (29)

Country Link
US (7) US7192923B2 (fr)
EP (4) EP1724283B1 (fr)
JP (3) JP4489434B2 (fr)
KR (3) KR100758857B1 (fr)
CN (3) CN1617887A (fr)
AR (3) AR038142A1 (fr)
AT (4) ATE334147T1 (fr)
AU (2) AU2003205197B2 (fr)
BR (3) BR0306826A (fr)
CA (3) CA2470731C (fr)
CY (1) CY1106133T1 (fr)
DE (4) DE60313845T2 (fr)
DK (2) DK1465921T3 (fr)
ES (4) ES2309909T3 (fr)
IL (5) IL162431A0 (fr)
MA (3) MA27590A1 (fr)
MX (3) MXPA04006884A (fr)
MY (1) MY140306A (fr)
NO (3) NO20043366L (fr)
NZ (3) NZ533599A (fr)
PE (3) PE20030849A1 (fr)
PL (3) PL371364A1 (fr)
PT (2) PT1465923E (fr)
RU (1) RU2294333C2 (fr)
SA (3) SA03230564B1 (fr)
SI (1) SI1465921T1 (fr)
TW (3) TW200302278A (fr)
WO (3) WO2003062277A1 (fr)
ZA (1) ZA200404995B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289916A1 (en) * 2000-09-22 2002-04-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
AU2006235045A1 (en) * 2005-03-30 2006-10-19 J. Craig Venter Institute, Inc. Haemophilus influenzae type b
WO2007090087A2 (fr) * 2006-01-27 2007-08-09 Research Development Foundation Inhibiteurs du recepteur 2 du facteur de liberation de la corticotrophine et ses utilisations
AU2008303893A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
WO2009043469A2 (fr) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046874A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Polythérapie de peptide potentialisateur de la trh et de stresscopine
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
EP2206726A1 (fr) * 2009-01-08 2010-07-14 Universite Joseph Fourier Outils non invasifs pour la détection de plaques athérosclérotique vulnérables
KR20120103606A (ko) * 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
WO2013063046A1 (fr) 2011-10-24 2013-05-02 Research Development Foundation Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine
JP6562632B2 (ja) * 2012-02-14 2019-08-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190084055A (ko) 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途
WO2025184558A1 (fr) * 2024-02-28 2025-09-04 Caradon Therapeutics, Inc. Urocortine 3 modifiée
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2025230248A1 (fr) * 2024-04-30 2025-11-06 한미약품 주식회사 Utilisation d'un agoniste du récepteur crf2 et d'un conjugué acylé associé
WO2026139062A1 (fr) * 2024-12-26 2026-07-02 杭州先为达生物科技股份有限公司 Agoniste du récepteur 2 du facteur de libération de la corticotropine et utilisation de celui-ci

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5824771A (en) * 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) * 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
AU6277796A (en) 1995-06-13 1997-01-15 Salk Institute For Biological Studies, The Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
ATE408622T1 (de) 2000-08-04 2008-10-15 Res Dev Foundation Urocortinproteine und deren verwendungen
AU2001289916A1 (en) * 2000-09-22 2002-04-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
CN1617887A (zh) 2005-05-18
AR038143A1 (es) 2004-12-29
RU2004124847A (ru) 2005-04-20
EP1465922B1 (fr) 2008-01-09
AU2003237419B2 (en) 2006-04-13
NZ533599A (en) 2007-03-30
US7192924B2 (en) 2007-03-20
RU2294333C2 (ru) 2007-02-27
TW200302278A (en) 2003-08-01
SA03230564B1 (ar) 2006-10-31
EP1465923B1 (fr) 2007-05-16
HK1078095A1 (zh) 2006-03-03
PE20030849A1 (es) 2003-12-01
NO20043371L (no) 2004-10-06
MXPA04006884A (es) 2004-12-06
SI1465921T1 (sl) 2006-10-31
US20030148958A1 (en) 2003-08-07
KR20040082389A (ko) 2004-09-24
SA03230565B1 (ar) 2006-10-31
PL373139A1 (en) 2005-08-22
AR038144A1 (es) 2004-12-29
BR0306838A (pt) 2005-04-05
MXPA04006885A (es) 2004-12-06
EP1465923A1 (fr) 2004-10-13
CN1617885A (zh) 2005-05-18
KR100758858B1 (ko) 2007-09-14
CA2470731C (fr) 2011-06-21
CA2470731A1 (fr) 2003-07-31
KR100735586B1 (ko) 2007-07-04
JP2005525101A (ja) 2005-08-25
TW200302277A (en) 2003-08-01
JP2005521387A (ja) 2005-07-21
DE60318547T2 (de) 2008-12-24
NZ533598A (en) 2007-03-30
IL197774A0 (en) 2009-12-24
KR20040082390A (ko) 2004-09-24
DE60321730D1 (de) 2008-07-31
WO2003062268A2 (fr) 2003-07-31
ES2309909T3 (es) 2008-12-16
PT1465921E (pt) 2006-12-29
AR038142A1 (es) 2004-12-29
ZA200404995B (en) 2005-06-29
WO2003062269A3 (fr) 2003-11-06
IL162529A0 (en) 2005-11-20
US7897731B2 (en) 2011-03-01
US20030148957A1 (en) 2003-08-07
MXPA04006883A (es) 2004-12-06
DE60318547D1 (de) 2008-02-21
EP1465921B1 (fr) 2006-07-26
PT1465923E (pt) 2007-08-06
SA03230564A (ar) 2005-12-03
MY140306A (en) 2009-12-31
ES2299701T3 (es) 2008-06-01
ATE362488T1 (de) 2007-06-15
IL196384A0 (en) 2011-07-31
EP1465922A2 (fr) 2004-10-13
DK1465921T3 (da) 2006-11-27
KR20040082392A (ko) 2004-09-24
CA2470743C (fr) 2011-12-13
ES2269976T3 (es) 2007-04-01
WO2003062268A3 (fr) 2003-11-27
US20090124793A1 (en) 2009-05-14
CN100391972C (zh) 2008-06-04
JP4508649B2 (ja) 2010-07-21
US7632933B2 (en) 2009-12-15
US7192923B2 (en) 2007-03-20
WO2003062269A2 (fr) 2003-07-31
IL162530A0 (en) 2005-11-20
TW200302276A (en) 2003-08-01
US20100197579A1 (en) 2010-08-05
JP4508648B2 (ja) 2010-07-21
CN100475844C (zh) 2009-04-08
ES2287484T3 (es) 2007-12-16
PL371364A1 (en) 2005-06-13
DE60307044D1 (de) 2006-09-07
US6936585B2 (en) 2005-08-30
EP1724283B1 (fr) 2008-06-18
CA2470656C (fr) 2011-06-28
EP1724283A2 (fr) 2006-11-22
US7462597B2 (en) 2008-12-09
DE60313845T2 (de) 2008-01-31
TWI300442B (en) 2008-09-01
CA2470656A1 (fr) 2003-07-31
EP1724283A3 (fr) 2007-04-11
BR0306826A (pt) 2005-09-06
ATE383372T1 (de) 2008-01-15
DK1465923T3 (da) 2007-07-02
PE20030974A1 (es) 2003-12-26
DE60307044T2 (de) 2007-02-15
US20060025339A1 (en) 2006-02-02
PE20030747A1 (es) 2003-10-23
CN1617886A (zh) 2005-05-18
US7608701B2 (en) 2009-10-27
US20030148956A1 (en) 2003-08-07
JP4489434B2 (ja) 2010-06-23
WO2003062277A1 (fr) 2003-07-31
US20080004435A1 (en) 2008-01-03
BR0306878A (pt) 2004-10-26
ATE398632T1 (de) 2008-07-15
ATE334147T1 (de) 2006-08-15
DE60313845D1 (de) 2007-06-28
AU2003205197B2 (en) 2006-03-02
EP1465921A2 (fr) 2004-10-13
JP2005522191A (ja) 2005-07-28
SA03230565A (ar) 2005-12-03
MA27590A1 (fr) 2005-11-01
NO20043396L (no) 2004-10-06
NZ533600A (en) 2007-02-23
PL373529A1 (en) 2005-09-05
KR100758857B1 (ko) 2007-09-14
IL162431A0 (en) 2005-11-20
NO20043366L (no) 2004-10-06
CA2470743A1 (fr) 2003-07-31
MA27591A1 (fr) 2005-11-01
CY1106133T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
MA27590A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
TW200609231A (en) Mglur1 antagonists as therapeutic agents
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
EA200500250A1 (ru) Аналоги тиомолибдата и их применение
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
MA31767B1 (fr) Composes organiques et leurs utilisations
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
SG127739A1 (en) Use of immuno-regulators
MA27063A1 (fr) Derives d'acide acetique d'indane et leur utilisation en tant qu'agents therapeutiques, produits intermediaires, et leur methode de preparation
GEP20074197B (en) 5ht2c receptor modulators
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
WO2001054681A8 (fr) Composition anti-stress
MA28038A1 (fr) Thienopyrazoles
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
EA200700909A1 (ru) Азаиндолкарбоксамиды